Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis

Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis

Background For the time being, tafamidis is the only approved treatment for wild‐type transthyretin cardiac amyloidosis. However, benefits on all‐cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Paolo Milani, Giuseppe Damiano Sanna, Roberta Mussinelli, Marco Basset, Gianluigi Guida, Andrea Attanasio, Martina Nanci, Francesca Fabris, Claudia Bellofiore, Alessandro Fogliani, Elisa Novello, Francesca Benigna, Laura Obici, Pietro Benvenuti, Martina Ciardo, Mario Nuvolone, Manuela Averaimo, Gavino Casu, Andrea Foli, Stefano Perlini, Giampaolo Merlini, Giovanni Palladini
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
amyloidosis
biomarkers
prognosis
staging
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.036755
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.036755

Similar Items